SMARTSCAN is connected to IBA Dosimetry’s Integrated Quality Assurance platform myQA®.
“Commissioning is a very intensive effort for medical physicists that not only requires in-depth experience but a lot of time to measure and analyze about 1,000 beam scans” said Jean-Marc Bothy, President of IBA Dosimetry GmbH. “As the inventors of computerized water phantoms, and with over 40 years of experience, we designed a brand new solution. SMARTSCAN defines state of the art in beam commissioning and annual Linac QA.”
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About SMARTSCAN™
SMARTSCAN is the efficient and precise solution to operate Linac and RTPS beam commissioning and annual QA. It guides the user efficiently through the whole workflow and automates repetitive tasks. SMARTSCAN is designed to deliver optimal beam data quality with highest standards in the shortest time – constantly. This is the optimal basis for accurate patient treatments and fast implementation of new Linac and RTPS equipment and annual QA.
SMARTSCAN is a trademark of IBA.
About IBA Dosimetry
IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
Back to HCB News
